IntelGenx to Report Third Quarter 2022 Financial Results on November 10, 2022 – Conference Call to Follow
IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) is set to release its third quarter 2022 financial results after market close on November 10, 2022. The results will be discussed in a conference call hosted by CEO Dr. Horst G. Zerbe and CFO Andre Godin at 4:30 p.m. ET. This update is crucial for stakeholders as the company focuses on its innovative pharmaceutical films, including technologies like VersaFilm® and VetaFilm™, addressing unmet medical needs.
- Potential for significant growth in pharmaceutical film technologies.
- Upcoming financial results may indicate positive business developments.
- None.
SAINT LAURENT, Quebec, Nov. 03, 2022 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its third quarter 2022 financial results after market close on Thursday, November 10, 2022.
An accompanying conference call will be hosted by Dr. Horst G. Zerbe, Chief Executive Officer, and Mr. Andre Godin, President and Chief Financial Officer, to discuss the results and provide a business update. Details of the conference call and webcast are below:
Third Quarter 2022 Results Conference Call Details:
| Date: | Thursday, November 10, 2022 |
| Time: | 4:30 p.m. ET |
| Live Call: | 1- 844-369-8770 (Canada and the United States) |
| 1- 862-298-0840 (International) | |
| Access Code: | INTELGENX |
The call will also be broadcast live and archived on the Company's website at www.intelgenx.com under "Webcasts" in the Investors section.
About IntelGenx
IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.
IntelGenx’s superior film technologies, including VersaFilm®, DisinteQ™, VetaFilm™ and transdermal VevaDerm™, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.
IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. For more information, visit www.intelgenx.com.
Forward-Looking Information and Statements
This document may contain forward-looking information about IntelGenx's operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx's plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx's actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx's annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.
Source: IntelGenx Technologies Corp.
For IntelGenx:
Stephen Kilmer
Investor Relations
(647) 872-4849
stephen@kilmerlucas.com
Or
Andre Godin, CPA, CA
President and CFO
IntelGenx Corp.
(514) 331-7440 ext 203
andre@intelgenx.com
FAQ
When will IntelGenx release its third quarter 2022 financial results?
What time is the IntelGenx conference call for the third quarter results?
Who will be discussing the financial results during the conference call?
What is the stock symbol for IntelGenx?
